166 related articles for article (PubMed ID: 35577706)
1. Immunotherapy for Colorectal Cancer.
Mukherji R; Weinberg BA; Pedersen KS
Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
[TBL] [Abstract][Full Text] [Related]
2. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
[TBL] [Abstract][Full Text] [Related]
4. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
5. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
Liang T; Tong W; Ma S; Chang P
Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
7. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of metastatic colorectal cancer with synchronous
Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
Lengyel CG
Curr Drug Targets; 2021; 22(9):968-976. PubMed ID: 33970843
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
11. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
Liu N; Shan F; Ma M
Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
[TBL] [Abstract][Full Text] [Related]
12. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review).
Choucair K; Radford M; Bansal A; Park R; Saeed A
Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34396449
[TBL] [Abstract][Full Text] [Related]
13. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.
Bartley AN; Mills AM; Konnick E; Overman M; Ventura CB; Souter L; Colasacco C; Stadler ZK; Kerr S; Howitt BE; Hampel H; Adams SF; Johnson W; Magi-Galluzzi C; Sepulveda AR; Broaddus RR
Arch Pathol Lab Med; 2022 Oct; 146(10):1194-1210. PubMed ID: 35920830
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy regimens for metastatic colorectal carcinomas.
Bashir B; Snook AE
Hum Vaccin Immunother; 2018 Feb; 14(2):250-254. PubMed ID: 29083978
[TBL] [Abstract][Full Text] [Related]
15. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
Wang D; Zhang H; Xiang T; Wang G
Front Immunol; 2021; 12():762341. PubMed ID: 34721435
[TBL] [Abstract][Full Text] [Related]
19. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
Tan E; Sahin IH
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
[No Abstract] [Full Text] [Related]
20. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
Lee V; Murphy A; Le DT; Diaz LA
Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
